Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world outcomes associated with switching to anti-TNFs versus other biologics in Crohn's Disease patients: A retrospective analysis using German claims data.
Zhuleku E, Antolin-Fontes B, Borsi A, Nissinen R, Bravatà I, Barthelmes JN, Le Bars M, Lee J, Passey A, Maywald U, Deiters B, Bokemeyer B, Wilke T, Ghiani M. Zhuleku E, et al. Among authors: bokemeyer b. Therap Adv Gastroenterol. 2022 Nov 4;15:17562848221130554. doi: 10.1177/17562848221130554. eCollection 2022. Therap Adv Gastroenterol. 2022. PMID: 36353736 Free PMC article.
Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.2).
Kucharzik T, Dignass A, Atreya R, Bokemeyer B, Esters P, Herrlinger K, Kannengiesser K, Kienle P, Langhorst J, Lügering A, Schreiber S, Stallmach A, Stein J, Sturm A, Teich N, Siegmund B; Collaborators. Kucharzik T, et al. Among authors: bokemeyer b. Z Gastroenterol. 2024 May;62(5):769-858. doi: 10.1055/a-2271-0994. Epub 2024 May 8. Z Gastroenterol. 2024. PMID: 38718808 Free article. German. No abstract available.
[Update: Addendum to S3-Guidelines Crohn disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease with regard to COVID-19 (version 2.0)].
Schmidt C, Stallmach A, Sturm A, Bachmann O, Helwig U, Koletzko S, Lynen P, Schnoy E, Dignass A, Kucharzik T, Blumenstein I; Collaborators. Schmidt C, et al. Z Gastroenterol. 2024 Apr;62(4):517-534. doi: 10.1055/a-2255-7184. Epub 2024 Apr 10. Z Gastroenterol. 2024. PMID: 38599579 German. No abstract available.
Inflammatory bowel disease (IBD) patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomised controlled trial in Germany (IBDBIO-ASSIST study).
Bokemeyer B, Plachta-Danielzik S, Steiner IM, Pohlschneider D, Urzica E, Hartmann P, Zemke J, Tappe U, Schreiber S, Steinkat N, Langbrandtner J, Hüppe A, Stargardt T. Bokemeyer B, et al. Aliment Pharmacol Ther. 2024 May;59(9):1082-1095. doi: 10.1111/apt.17926. Epub 2024 Mar 1. Aliment Pharmacol Ther. 2024. PMID: 38429885 Clinical Trial.
Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.1) – Februar 2023 – AWMF-Registriernummer: 021-009.
Kucharzik T, Dignass A, Atreya R, Bokemeyer B, Esters P, Herrlinger K, Kannengiesser K, Kienle P, Langhorst J, Lügering A, Schreiber S, Stallmach A, Stein J, Sturm A, Teich N, Siegmund B; Collaborators:. Kucharzik T, et al. Among authors: bokemeyer b. Z Gastroenterol. 2023 Aug;61(8):1046-1134. doi: 10.1055/a-2060-0935. Epub 2023 Aug 14. Z Gastroenterol. 2023. PMID: 37579791 Free article. German. No abstract available.
Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naïve Crohn's Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study.
Bokemeyer B, Plachta-Danielzik S, di Giuseppe R, Efken P, Mohl W, Hoffstadt M, Krause T, Schweitzer A, Schnoy E, Atreya R, Teich N, Trentmann L, Ehehalt R, Hartmann P, Schreiber S. Bokemeyer B, et al. Inflamm Bowel Dis. 2024 May 2;30(5):746-756. doi: 10.1093/ibd/izad138. Inflamm Bowel Dis. 2024. PMID: 37523666
126 results